Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis.

Johannes LaengleJulijan KabiljoLeah HunterJakob HomolaSophie ProdingerGerda Egger Michael M Bergmann

Published in: Journal for immunotherapy of cancer (2020)

HDACi VPA and SAHA increase trastuzumab-mediated phagocytosis and trastuzumab-independent cytotoxicity. The immunomodulatory activities of those HDACi support a rationale combined treatment approach with mAb for cancer treatment.

Keyphrases

histone deacetylase
epidermal growth factor receptor
metastatic breast cancer
clinical trial
single cell
stem cells
mesenchymal stem cells
combination therapy